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Canine influenza virus (CIV) subtype H3N2 is a newly identified, highly contagious respiratory pathogen that causes
cough, pneumonia and other respiratory symptoms in dogs. Data indicate that the virus is responsible for recent
clinical cases of dog disease in China. However, therapeutic options for this disease are very limited. In this study,
seven monoclonal antibodies (mAbs) against CIV JS/10 (an H3N2 subtype virus) were produced and characterized.
Among them, mAb D7, which is specific for the HA2 glycopeptide (gp), induced the highest neutralization titers.
The protection provided by mAb D7 was evaluated in BALB/c mice challenged with homologous or heterologous
strains of H3N2 influenza virus, including two strains of CIV and one strain of swine influenza virus (SIV). The data
show that mAb D7 protected the mice from infection with the three viral strains, especially the homologous strain,
which was indicated by the recovery of body weight, reduction of viral load, and reduction of tissue damage.
Moreover, the levels of IFN-γ and TNF-α in the lungs, as detected by ELISA, were reduced in the infected mice
treated with the mAb D7 compared with those without mAb D7 treatment. Thus, our findings demonstrate, for the
first time, that a mAb could reduce the release of IFN-γ and TNF-α associated with tissue damage by CIV infection
and that the mAb might be of great therapeutic value for CIV infection.Introduction
Influenza A virus, a highly contagious pathogen, can in-
fect both birds and mammals. It has undergone signifi-
cant genetic variation to adapt to different hosts [1]. Its
interspecific transmission is achieved by the recombin-
ation or direct transfer of genetic material [2]. The first
case of dog infection with H3N8 canine influenza virus
(CIV) was reported in the USA in 2004 [3,4], followed
by a report of CIV in South Korea, which subsequently
demonstrated that CIV was able to transmit directly
from dog to dog [5,6]. Recently, the first case of H3N2
CIV infection was reported in Guangdong Province in
2010 [7]. Over recent years, infection with H3N2 CIV in
dogs has developed from scattered cases to wide distri-
bution across the country [8-10]. Dogs have no natural
immunity to this virus, thus a number of preventive and
therapeutic measures against CIV have been attempted
to control the prevalence of this virus. Among them,
vaccination is an important method to prevent and
control influenza virus infection [11-13]. Current vaccine* Correspondence: liuyongjie@njau.edu.cn
College of Veterinary Medicine, Nanjing Agricultural University, Nanjing,
China
© 2015 Xie et al.; licensee BioMed Central. Thi
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.research against CIV has made some progress. In 2009,
the U.S. Department of Agriculture (USDA) approved a
list of vaccines against H3N8 CIV, which could effec-
tively reduce viral shedding [14]. In 2012, the patent for
an H3N2 CIV vaccine in South Korea was also approved
[15]. Preventive vaccination is historically the primary
measure to control influenza virus infection, but it has
some limitations [16]. For example, influenza vaccines
may not be effective enough to prevent against divergent
viral strains, or may be less immunogenic and effective
in certain groups, such as the very young, the old, and
the immunocompromised [17]. Therefore, it is crucial to
develop other measures to protect animals from infec-
tion/disease [18]. For example, passive immunity by
transferring a specific antibody to a recipient could pro-
tect animals from infection [19]. Monoclonal antibodies
(mAbs) can neutralize viruses, thus preventing virus
attachment to, or fusion with, the host cell [20]. Many
studies have demonstrated that mAbs are an effective
and preventive treatment against human-origin [21-23]
or avian-origin influenza virus infection [11,24,25]. How-
ever, to date, there are no neutralizing mAbs available to
prevent and control H3N2 CIV infection.s is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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CIV, and tested one of them, the D7 mAb, against three
different H3N2 subtype virus strains in animal experi-
ments. This is the first description of a neutralizing mAb
against H3N2 CIV.
Materials and methods
Virus strains, cells and medium
Three viral strains of the H3N2 subtype, including A/
Canine/Jiangsu/06/2010 (JS/10), A/Canine/Guangdong/
12/2012 (GD/12) and A/swine/Shandong/3/2005 (SD/05)
were used in this study. The GenBank accession numbers
of JS/10, GD/12 and SD/05 are JN247616 to JN247623,
KF826944 to KF826951 and EU116037 to EU116044,
respectively. The three viral strains were adapted to mice
by passaging 3 times. They were propagated in 10-day-old
specific-pathogen free (SPF) embryonated chicken eggs and
stored at −70 °C before use.
Madin-Darby canine kidney (MDCK) cells were cul-
tured in Dulbecco’s modified essential medium (DMEM)
containing 10% (v/v) fetal bovine serum (Hyclone, tah,
USA) and maintained at 37 °C and in a 5% (v/v) CO2
atmosphere.
Experimental animals
BALB/c mice (6 weeks old, female) were purchased from
the Animal Experiment Center, Yangzhou University. All
animal experiments complied with the guidelines of
the Animal Welfare Council of China, and the Animal
Ethics Committee of Nanjing Agricultural University
approved the study.
Fifty-percent tissue culture infective dose (TCID50) assays
One day before infection, a 96-well dish containing a
monolayer of MDCK cells was prepared. The next day,
serial dilutions of the three influenza virus strains were
made, and the cell monolayers were laterally inoculated;
each dilution had three replicates. The cytopathic effect
(CPE) was observed daily and the numbers of wells for a
virus dilution that showed more than and less than
50% pathological changes were recorded. TCID50 titers
were calculated in accordance with the Reed-Muench
method [26].
Generation of H3N2 mAbs
Canine influenza virus JS/10 was grown in 10-day-old SPF
embryonated chicken eggs at 37 °C for 72 h. Allantoic
fluids were harvested and the hemagglutination (HA)
activity of the allantoic fluids was tested at room tem-
perature using 1% chicken red blood cells (RBC). HA
titers more than or equal to 1:64 were selected, and the
virus was purified using differential centrifugation and su-
crose density gradient centrifugation. Preparation of
anti-H3 mAbs followed standard hybridoma technology,as previously described [27]. Six-week-old female BALB/c
mice were injected intracutaneously with 100 μg of puri-
fied virus JS/10 using complete Freund’s adjuvant (Sigma,
Beijing, China) as the primary adjuvant, followed by in-
complete Freund’s adjuvant. Three days before harvesting
the splenocytes, 100 μg of JS/10 were inoculated intraven-
ously. Isolation and screening of the hybridomas was per-
formed as described previously [28]. MAbs were prepared
by injecting hybridoma cells into the peritoneal cavities of
pristane-primed BALB/c mice. The ascetic fluid was col-
lected after 9–12 days and inactivated at 56 °C for 30 min.
Hemagglutination inhibition (HI) and microneutralization
tests
The HI test was performed to assess antibody reactivity
against three H3N2 strains, JS/10, GD/12 and SD/05, as
previously described [29]. Briefly, 25 μL of serial two-
fold dilutions of the purified 5-fold diluted ascetic fluid
of the mAb were mixed with 4 HA units of virus in dis-
posable hemagglutination plates and incubated at 37 °C
for 30 min. Then, 25 μL of 1% chicken RBC were added
to each well and incubated at room temperature for 30
min. To rule out non-specific inhibition, in the HI assay,
we used the ascetic fluid produced with the injection of
SP2/0 myeloma cells as a negative control. The HI titer
was expressed as the reciprocal of the highest serum
dilution that completely inhibited hemagglutination of 4
HA units of the virus [30].
Cell-based neutralization assays were performed as
previously described [31]. A dose of 100 TCID50 of viru-
ses was used in the assays. Supernatants of ascites were
tested at a starting dilution of 1:25. Briefly, two-fold dilu-
tions of hybridoma supernatants were mixed with virus
suspension containing 100 TCID50 of purified H3N2
virus and incubated at 37 °C in a 5% CO2 incubator for
1 h before their addition to a monolayer of MDCK cells
in 96-well plates. One hundred microliters of serum-free
DMEM was added to each well and incubation at 37 °C
continued for 1 h. The cytopathic effect was observed
every 24 h for 48 to 72 h.
Antigen identification of MAbs
To determine the recognized HA domain of the MAbs,
we recombinantly expressed the HA, HA1 and HA2
proteins of virus JS/10. The recombinant proteins were
subjected to SDS-PAGE under reducing conditions. The
proteins were then electro-transferred and immobilized
on a nitrocellulose membrane. The membrane was
blocked with 5% nonfat milk in phosphate buffered
saline (PBS) containing 0.1% Tween 20 (PBST) at 37 °C
for 1 h. The membrane was subsequently incubated with
the mAb prepared in this study, rinsed in PBST, and in-
cubated with horseradish peroxidase (HRP)-conjugated
rabbit anti-mouse immunoglobulin (Bio-Rad, Shanghai,
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agents (Tiangen, Beijing, China) [32].
Cross-protection by H3-specific mAb
BALB/c mice were used to determine the protective
efficacy of mAb D7. Intranasal inoculations with 107
TCID50 of virus strains JS/10, GD/12 and SD/05 were
given to experimental groups I (n = 45), II (n = 45) and
III (n = 45), respectively; the control group received PBS
(n = 15). Each experimental group was divided into
three subgroups (n = 15 for each subgroup), which were
the virus-infected, mAb D7 and irrelevant mAb IgG sub-
groups, respectively. Mice injected with PBS or irrele-
vant mAb IgG were considered as blank and negative
controls, respectively. For the mAb D7 and irrelevant
mAb IgG subgroups, mice were pretreated intraperito-
neally with mAb D7 (36 μg/mL) or irrelevant mAb IgG
(32 μg/mL) against IgM from Chinese breams developed
in our laboratory, at a dose of 20 mg per kg of body
weight in 100 μL of PBS before the viral challenge
[24,33,34]. After 24 h, mice were challenged with three
different H3N2 strains. Mice were observed daily to
monitor body weight and clinical symptoms for up to 14
days.
Three mice from each subgroup were euthanized hu-
manely according to a pre-designated schedule. At 2, 4,
6, 10 and 14 days post-infection (dpi), blood samples
and tissues including heart, spleen, lung, brain and intes-
tine, as well as feces were collected. Virus shedding was
detected by screening fecal samples. Detection of viral
RNA was used to determine tissue distribution and virus
shedding. Tissues and feces were homogenized in lysates
at a ratio of 1:1 (g/mL), respectively, centrifuged at
10 000 × g for 30 min, and the supernatants were collected
for the extraction of viral RNA using the Virus Nucleic
Acid Extraction Kit II (Geneaid, Taiwan). All tissues col-
lected above, including blood, were used for virus titration;
the lung, brain and heart were also used for histological
and immunohistochemical analysis at 6 dpi.
Real-time PCR for quantitation of viral loads
Quantitative assays were carried out to measure viral
loads in the blood and main organs [33]. Total RNA
from tissues and blood samples was reverse transcribed
using the PrimeScript™ RT reagent Kit with gDNA
Eraser (Perfect Real Time) (Takara, Dalian, China) and
then run on an ABI 7500 Real Time PCR System using
the SYBR1 Premix Ex TaqTM (Perfect Real Time) kit
(Takara). Reverse transcription and cDNA amplification
were carried out as described previously [8]. The primers
used were designed against a region of the matrix gene:
5′- TCTATCGTCCCATCAGGC/GGTCTTGTCTTTAG
CCATTC-3′. A reference standard was prepared using
pMD19-T Simple Vector (50 ng/μL; Takara) that containedthe corresponding target virus sequences. A series of eight
10-fold dilutions equivalent to 1 × 103–1 × 1010 copies per
reaction were prepared to generate calibration curves and
were run in parallel with the test samples [35]. RNA of the
amount of the two avian-origin CIV and human-origin
influenza viruses was calculated from the standard curve
by real-time RT-PCR. The detection limit of this assay was
1120 copies of RNA per mL.
Histopathology and immunohistochemical analysis
After euthanasia at 6 dpi, the heart, brain and lung from
the mice inoculated with JS/10, GD/12, SD/05 or PBS
were collected and placed into 10% neutral buffered for-
malin. After fixation the tissues were embedded in paraf-
fin, sectioned at 4 μm and stained with hematoxylin and
eosin for histological evaluation. Sequential slides were
stained using an immunoperoxidase method [8].
Expression of hemagglutinin in tissues was examined by
immunohistochemical staining of histological sections.
In brief, sections were blocked with 1% bovine serum
albumin/PBS, stained with mAb D7 at a dilution of 1:5000
for one hour at 37 °C, followed by biotin conjugated goat
anti-mouse immunoglobulin (Bio-Rad) at a dilution of
1:200 for 30 min at 37 °C. The sections were subsequently
incubated with HRP conjugated streptavidin (Bio-Rad)
at 37 °C for 30 min. Sections were then developed with
HRP-DAB chromogenic substrate kit (Tiangen) for 10
min and counterstained with hematoxylin. The lungs were
assigned a grade of 0 to 3 based on the histological charac-
ter of the lesions. Score criteria of different grades were in
accordance with a previous study [36].
Measurement of cytokines
We further investigated if there was a correlation bet-
ween severe disease and inflammatory cytokine produc-
tion in virus-challenged mice, and ascertained whether
passive immunization with antibodies affected the levels
of cytokines involved in defense against three different
influenza virus infections. Sections of the lungs (alternating
right and left lungs) from all the mice were homogenized in
1 mL of PBS per 1 g of lung tissue. The homogenates were
centrifuged, and the supernatants were frozen at −70 °C
until tested. The supernatants were assayed for gamma
interferon (IFN-γ) and tumor necrosis factor (TNF-α)
using ELISA kits (Sigma-Aldrich, Beijing). The minimum
detection limits of such assays were as follows: 25 pg/mL
for TNF-α and 10 pg/mL for IFN-γ, as previously deter-
mined by the manufacturer.
Statistical analysis
Data were collected and analyzed using MS Excel 2010
and SPSS Statics v20.0 software. Weight loss, viral titers,
cytokine levels and histological score were analyzed by
analysis of variance (ANOVA), followed by Turkey’s
Table 1 Characteristics of seven monoclonal antibodies
(mAbs) direct against JS/10
mAb Isotype Neutralization titer HI titer
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a significant difference, while P < 0.01 was considered to
be statistically extremely significant.B6 IgG2a 1600 320
B7 IgG2b 1600 80
B8 IgG2b 800 40
D7 IgG2b 12800 0
D8 IgG2b 6400 160
G6 IgG2b 400 20Results
Virus titers
CIV was propagated in MDCK cells and the titers of
three viral strains, JS/10, GD/12 and SD/05 were deter-
mined to be 107.13 TCID50/mL, 10
7.25 TCID50/mL and
108 TCID50/mL, respectively.H9 IgG2b 100 20Characterization of mAbs
After fusion between spleen cells from H3N2 virus-
immunized mice and sp2/0 myeloma cells, we obtained
seven mAbs against the JS/10 virus. Isotyping tests
showed that all of these mAbs were IgG2b isotypes,
except for one that was IgG2a. Of the seven mAbs iden-
tified, four mAbs reacted with HA. Among these four
mAbs, mAb D7 reacted with HA2 and three other mAbs
reacted with HA1 (Figure 1), as demonstrated by
western blotting. HI and neutralization titers of the
seven mAbs showed that mAb D7 had the highest
neutralization activity, but had no HI activity (Table 1).
Further analysis indicated that mAb D7 could react with
virus strains JS/10, GD/12 and SD/05, and produce highFigure 1 Antigen identification of mAb D7 by western blotting
using recombinant proteins HA, HA1 and HA2. Lane M, protein
pre-stained mass markers; Lane 1, mAb D7 reacted with expressed
viral protein HA; Lane 2, mAb D7 reacted with recombinant protein
HA1 (not visualized here); Lane 3, mAb D7 reacted with expressed
protein HA2. Viral proteins were identified by DAB staining with
HRP-labeled goat anti-mouse secondary antibody.neutralization activities against the three viral strains,
especially against the homologous strain JS/10 (Table 2).
MAb D7 in the treatment of influenza in mice
To access the protective efficacy of mAb D7, we inocu-
lated mice with three different H3N2 strains one day
after treatment with mAb D7. Three days after the
inoculation, all mice challenged with the three virus
strains exhibited clinical signs of infection, including de-
pression, decreased activity and huddling. Similar clinical
signs were observed in irrelevant mAb IgG pretreated
groups. However, similar to the PBS control group, mice
in mAb D7 pretreated groups seemed to be energetic
and had a good appetite during the infection.
In terms of body weight, mice challenged with JS/10
after treatment with D7 showed a similar increase in
body weight compared with the PBS control group and
there was no significant difference between the two
groups (Figures 2A, B and C). At 14 dpi, mice treated
with mAb D7 showed a body weight increase of nearly
30%. Although the body weights in the virus-infected
group and irrelevant mAb IgG group both demonstrated
an upward trend, the growth rate was slower than that
in the mAb D7 group. The extent of the increase in
body weight was significantly slower compared with that
of the mAb D7 group at 10, 12 and 14 dpi (P < 0.05)
(Figure 2A). In the group of mice infected with GD/12,
the body weights of the mice in the three experimental
groups all showed an upward trend, but the growth rate
of the mice treated with mAb D7 was much higher than
in the other two groups. In addition, the body weight
changes of mice in the mAb D7 group at 10, 12 and 14Table 2 Characteristics of monoclonal antibody (mAb) D7
direct against virus strains JS/10, GD/12 and SD/05
Virus
strains
mAb D7 mAb IgG
Neutralization titer HI titer Neutralization titer HI titer
JS/10 12800 0 0 0
GD/12 6400 0 0 0
SD/05 3200 0 0 0
Figure 2 Body weight changes and viral loads in the lungs of mice treated with mAb D7. Three groups of 6-week-old BALB/c mice were
challenged with approximately 107 TCID50 of strains JS/10 (A, D), GD/12 (B, E) and SD/05 (C, F), respectively. In each virus group, mice were
pretreated with 20 mg/kg of mAb D7, mAb IgG or PBS 1 day before viral challenge. Mice were monitored for body weight loss throughout
the 14-day observation period. For body weight change (A, B, C), the results are expressed in terms of percent body weight. *P < 0.05, or
**P < 0.01, indicates a significant difference in weight data for the mAb D7 treated groups compared with the virus-infected groups and irrelevant
mAb IgG groups. # P < 0.05, indicates a significant difference in weight data for the PBS group compared with the mAb D7 treated group. For
viral loads in the lungs (D, E, F), the results are expressed in terms of mean log10 number of copies/g of RNA standard deviation. *P < 0.05, or
**P < 0.01, indicates a significantly different virus titer for the mAb D7 group compared with the other two groups. 2/3, and 1/3, indicate the
proportion of the lungs in which virus could be detected.
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two experimental groups (P < 0.05). The mice in the
mAb D7 group showed weight gains of nearly 30%,which was not significantly different from the PBS
control group (Figure 2B). However, after infection with
SD/05, mice in the virus-infected group showed a slight
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IgG group displayed a slight decline at 8 dpi. By
contrast, mice in the mAb D7 group continued to grow
at 8 (P < 0.05), 12 (P < 0.01) and 14 dpi (P < 0.01). The
growth rate in the mAb D7 group was significantly
higher than that in the virus-infected group and mAb
IgG group, but slightly lower than in the PBS control
group at 14 dpi; mice body weight gain in the mAb
group reached approximately 25% (Figure 2C).
Quantitation of viral RNA loads
Real-time PCR was used to evaluate the kinetics of viral
RNA loads in the lung, heart, brain, spleen, intestine,
feces and blood of the infected mice. The viral titers
were expressed as the number of copies of viral RNA.
The dynamic changes of viral titers in the lungs of mice
in the virus-infected group, mAb D7 group and irrele-
vant mAb IgG group were similar: peak viral titers were
observed at 2, 4 and 6 days after infection, after which
the viral titer declined at 10 and 14 dpi (Figures 2D, E
and F). However, viral titers in the lungs of mice treated
with mAb D7 were significantly lower than in the mice in
the other two groups at specific time points. After challenge
with JS/10, viral loads in lungs of mice treated with mAb
D7 were significantly lower than those in the other two
groups at 4, 6 and 10 dpi (P < 0.01) (Figure 2D). For strain
GD/12, viral titers of the lungs in the mAb D7 group were
significantly lower compared with the other two experi-
mental groups at 4 (P < 0.05) and 6 dpi (P < 0.01). In
addition, at 10 and 14 dpi, viral RNA could not be detected
in some lung samples (1/3 and 2/3, respectively) in the
mAb D7 group (Figure 2E). For virus SD/05, the viral titer
of mice in the mAb D7 group was significantly lower than
in the other two groups at 6 (P < 0.05), 10 (P < 0.01)
and 14 dpi (P < 0.05) (Figure 2F). For mice in the
virus-infected group, peak viral titers of three virus
strains JS/10, GD/12 and SD/05 were 108.4, 107.3,
108.5copies/g, respectively, while for mice in the mAb
D7 group, peak values were 106.5, 106.4 and 107.8
copies/g, respectively.
Considering that mAb D7 resulted in a significant re-
duction in viral titers in the lungs of mice infected with
three different virus strains at 6 dpi, we chose that time
point to determine the viral RNA loads in different tis-
sues and fecal samples. We found that viral loads in col-
lected feces, blood and other tissues at 6 dpi in the mAb
D7 group were also lower than those in the other two
groups (Figure 3). After mice were challenged with virus
JS/10, viral titers of the lung, heart, intestine, feces and
blood in the mAb D7 group decreased by 192 (P < 0.01),
145 (P < 0.05), 20 (P < 0.05), 82 (P < 0.01) and 26
(P < 0.01) fold, respectively, compared to the other two
groups (Figure 3A). For mice challenged with virus
GD/12, viral titers of the lung, heart, spleen, feces andblood of mice treated with mAb D7 were found to be re-
duced by 103 (P < 0.01), 30 (P < 0.01), 25 (P < 0.05), 13
(P < 0.05) and 31 (P < 0.05) fold in comparison with the
other two groups (Figure 3B). For virus SD/05, mAb D7
resulted in a reduction in viral titers of the lung, spleen,
intestine, feces and blood by 13 (P < 0.05), 21 (P < 0.05),
57 (P < 0.05), 33 (P < 0.05) and 10 (P < 0.05) fold,
respectively (Figure 3C).
Generally, mAb D7 could reduce viral loads of the
three virus strains in the infected mice. Notably, in the
virus-infected group and irrelevant mAb IgG group,
after infection with virus JS/10, even till 14 dpi, virus
RNA was detected in most tissues, while for the mice
treated with mAb D7, virus RNA could not be detected
in the brain and almost all the other tissues, except for
the lung and blood, at 14 dpi (Additional file 1). For
virus GD/12, at 10 dpi, viral titers in all the detected
tissues were much lower compared with the other two
viruses, in all three groups. Viral titers in some tissues
were undetectable. Mice in the mAb D7 group showed a
much faster virus clearance rate than the other two
groups. At 10 dpi, no virus was detected in the intestines
and feces of three mice in the mAb D7 group and at 14
dpi, virus was undetectable in all the other tissues in
mice treated with mAb D7, except for the lungs in one
mouse (Additional file 2). However, in mice infected
with SD/05, the virus showed the longest retention time.
At 14 dpi, nearly all tissues from mice in virus-infected
and irrelevant mAb IgG groups showed detectable virus
RNA. Even in the mAb D7 group, all mice showed
positive virus RNA in the detected tissues, except for the
intestines and feces (Additional file 3).
Histopathological and immunohistochemical findings
To compare the above results with pathological findings
in mice infected with three different virus strains, and
treated with mAb D7 and irrelevant mAb IgG, we chose
the heart, brain and lung from different treatment
groups at 6 dpi to perform histopathological and immu-
nohistochemical analysis. All the sampled tissues from
mice in the virus-infected group showed significant
lesions and viral antigen staining, while those from the
control group did not show any lesions. Mice treated
with mAb D7 had markedly fewer lesions compared
with the virus-infected group (Figure 4). Histological
lesions in the mAb IgG group showed similar results
with those in the virus-infected group (data not shown).
Regardless of virus strain, the lung interstitial space
was obviously widened, and the bronchial lumen became
narrow, with the alveolar septum thickened by the infil-
tration of a number of inflammatory cells (Figures 4A
and C). Large areas of the lung appeared consolidated,
with symptoms of pulmonary congestion (Figure 4E).
Interstitial pneumonia was also obvious, with the alveolar
Figure 3 Viral loads in collected tissues and fecal samples of mice at 6 dpi. Mice were pretreated with 20 mg/kg of mAb D7, mAb IgG or
PBS 1 day before viral challenge with virus JS/10 (A), GD/12 (B) or SD/05 (C), respectively. In each virus group, the lung, heart, brain, spleen,
intestine, feces and blood of mice were collected for determination of viral loads using real-time PCR at 6 days post-challenge. *P < 0.05, or
**P < 0.01, indicates significantly different virus titers compared with the other two groups.
Xie et al. Veterinary Research  (2015) 46:33 Page 7 of 14
Xie et al. Veterinary Research  (2015) 46:33 Page 8 of 14septum and proliferation of connective tissue infiltrated
with numerous macrophages around the bronchioli and
blood vessels (Figures 4C and E). In brief, histological
lesions were characterized by multifocal to coalescing red-
dish consolidation in mice infected with the virus JS/10,
GD/12 or SD/05 in both the virus-infected and irrelevant
mAb IgG groups. However, the degree of histological le-
sions observed for SD/05 was the most severe, and GD/12
showed the least severe lesions among these three viruses.
Mice treated with mAb D7 showed only mild necrotizing
bronchiolitis and ciliated tracheal epithelium with mild
hyperplasia (Figure 4F). In addition, very small gaps were
observed between the alveoli and there were no excessive
amounts of alveolar macrophages in the lung (Figures 4B
and D). For virus strain GD/12, mAb D7 demonstrated
the best protective efficacy compared with the other two
viruses. Mice in the PBS group showed bronchia with a
simple ciliated columnar epithelium and the alveolar
cavity as a vacuolated thin-walled structure (Figure 4G).
Viral antigen staining was present in almost all bron-
chiolar epithelial cells and some alveolar cells at 6 dpi after
virus challenge (Figures 5A, C and E), while mice in mAb
D7 showed only a little virus antigen staining surrounding
vessels near the alveoli (Figures 5B, D and F). The PBS
control group had no viral staining (Figure 5G). Lung
grades for degree of injury at 6 dpi are shown in Figure 6.
There was significantly less injury to the lungs in the mAb
D7 group than in the virus-infected group and mAb IgG
group for all virus strains.
Similar to the lung, all mice in the virus-infected
groups showed histological lesions in the brain. TheFigure 4 Histopathological changes shown by H&E staining in the lun
mice in the virus-infected group (A, C, E, H, J, L, O, Q, S), the mAb D7 tre
shown, respectively. Short arrows indicate the lesions. All the images are shextent of histological lesions infected was the most se-
vere with SD/05 and was the least severe for GD/12.
The severity of the infection may depend on the differ-
ences in virus titer. In the cerebrum, congestion and
hemorrhage were evident. Nerve fibers were dissolved
and neurons had necrolysis-like vacuoles; glial nodules
and neuronophagia were also observed (Figures 4O and
Q). Dilation and hyperemia were found in the capillaries
(Figure 4S). Moreover, microglial cells and nerve cells
showed a satellite phenomenon. The cytoplasm of
the neurons was basophilic because of contraction
(Figures 4O and Q). Viral antigens could be detected in
glial nodules and microglial-gathered areas (Figures 5O,
Q, and S). The brains of mice treated with mAb D7 had
only mild lesions surrounding microglial cells and nerve
cells (Figures 4P and T), and almost no antigen staining
was found (Figures 5R and T). The PBS control group
showed no histological findings (Figure 4U) and no viral
staining (Figure 5U).
In the heart, for all mice in virus-infected groups, the
cardiac striated muscle was disordered and full of vacu-
oles, characterized by myocarditis, and lymphocyte infil-
tration was observed (Figure 4H). Lymphoproliferation
was also found among the muscle fibers (Figure 4J). The
nuclei showed pyknosis, with some myocardial cells
showing coagulative necrosis (Figures 4J and L), which
was consistent with heavy antigen staining (Figures 5H, J
and L). No significant differences in microscopic lesions
(Figures 4I, K, M and N) and viral antigen staining
(Figures 5I, K, M and N) were found between the mAb
D7 and PBS groups.g, heart and brain at 6 dpi. For each virus, selected tissues from
ated group (B, D, F, I, K, M, P, R, T) and the PBS group (G, N, U) are
own at 100 × magnification.
Figure 5 Immunohistochemical detection of influenza viral antigen in the lung, heart and brain at 6 dpi. For each virus, selected tissues
from mice in the virus-infected group (A, C, E, H, J, L, O, Q, S), the mAb D7 treated group (B, D, F, I, K, M, P, R, T) and the PBS group (G, N, U)
are shown, respectively. All the images are shown at 400 × magnification.
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To gain a better understanding of the effect of CIV on
the innate immune response and to ascertain whether
passive immunization with monoclonal antibody affected
the levels of cytokines, we examined the levels of IFN-γ
and TNF-α in the lungs of mice in the virus-infected
and mAb D7 groups.
As shown in Figure 7, the level of IFN-γ in response to
all three virus strains showed an identical trend, higher atFigure 6 The degree of lung injury after infection with virus
JS/10, GD/12 and SD/05 at 6 dpi. The lungs were assigned a grade
0 to 3 based on the histological character of the lesions. *P < 0.05, or
**P < 0.01, indicates a significantly different score for the mAb D7
group compared with the other two groups.2, 4 and 6 dpi than at 10 and 14 dpi. The IFN-γ levels in
mAb D7 group in all three virus strains were significantly
lower than the virus-infected group or mAb IgG group,
especially at 6, 10 and 14 dpi. However, the cytokine levels
differed with the various virus strains.
For virus strain JS/10, the IFN-γ level of all groups
reached its peak at 2 dpi, and then exhibited an overall
downward trend. The cytokine levels in the mAb D7
group at 6 (P < 0.01) and 10 dpi (P < 0.05) were signifi-
cantly lower than that in the virus-infected or mAb IgG
group; however, the IFN-γ level did not show any sig-
nificant difference among the three groups at other time
points (Figure 7A). The IFN-γ level in the mAb D7
group returned to normal after 10 dpi, while the other
two groups returned to the normal level at 14 dpi.
For virus strain GD/12, the IFN-γ levels of the three
experimental groups were significantly higher than in
the mice in the PBS group at 2 (P < 0.01), 4 (P < 0.01)
and 6 dpi (P < 0.01), sustaining a relatively high level
until 10 dpi, after which it decreased. The peak level of
IFN-γ in the mAb IgG group was lower compared with
the other two virus strains at 2 dpi (Figure 7B). Although
the IFN-γ levels in the three experimental groups chal-
lenged with GD/12 did not show much difference com-
pared with each other, the IFN-γ level in the mAb D7
group at 10 dpi returned to a normal level, which was
significantly lower (P < 0.05) compared with the other
two groups; all the three groups showed normal levels at
14 dpi.
For virus strain SD/05, this virus induced the largest
rise in IFN-γ levels. The level in the SD/05-infected
Figure 7 Characterization of IFN-γ and TNF-α secretion from lung tissues of mice challenged with virus. Cytokine concentrations were
measured by ELISA in supernatants of homogenates from the lungs infected with three virus strains. Mice were pretreated with 20 mg/kg of
mAb D7, mAb IgG or PBS 1 day before challenged with virus JS/10 (A, D), GD/12 (B, E) or SD/05 (C, F), respectively. The cytokine levels were
measured in the infected mice on days 2, 4, 6, 10 and 14 post challenged. The results are expressed in terms of pg/mL. *P < 0.05, or **P < 0.01
indicates significantly different changes for mAb D7 group compared with the virus-infected group or the mAb IgG group. # P < 0.05, or ## P < 0.01,
indicates a significant difference between this group and the PBS control group.
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viruses at 2 dpi. In addition, mice in virus-infected and
mAb IgG groups both demonstrated the same trend in
the period of 2 to 10 dpi (P < 0.01), i.e., significant ele-
vation followed by a downward trend (Figure 7C).Although the IFN-γ level in the mAb D7 group at 2 to
10 dpi was relatively high compared with the PBS group,
the IFN-γ levels were significantly lower than those
of the other two groups at 6 (P < 0.01) and 10 dpi
(P < 0.05), and then declined to the normal level at 14 dpi.
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for IFN-γ. After infection with the three virus strains,
TNF-α levels of mice in all groups were only slightly
higher than those of the PBS group at 2 dpi and in-
creased at 4 and 6 dpi. Levels reached their maximum at
10 dpi and decreased at 14 dpi, however, the cytokine
level was still higher than that of the control group at 14
dpi which was quite different compared with the IFN-γ
level. The increase in TNF-α level was lower compared
with the IFN-γ level. In addition, the TNF-α level in the
mAb D7 group was apparently lower than the virus-
infected group or mAb IgG group, especially at 10 and
14 dpi.
For virus strain JS/10, TNF-α levels in the virus-
infected group and mAb IgG group showed a small rise
at 2 dpi, reaching its peak at 6 dpi, and then declined;
however, the cytokine level was still significantly higher
(P < 0.05) than that of the PBS group (Figure 7D). The
TNF-α level in the mAb D7 group at 14 dpi (P < 0.05)
was remarkably lower than that in the virus-infected
group and mAb IgG group, and decreased to a similar
level as the PBS group.
For virus strain GD/12, the TNF-α level of all three
experimental groups increased from 2 to 6 dpi, and then
returned to normal at 14 dpi (Figure 7E). The TNF-α
level of the mAb D7 group at 10 dpi was significantly
lower (P < 0.05) than in the other two groups, while the
cytokine level did not show much difference in these
three groups at the other time points.
For virus strain SD/05, the TNF-α levels in the virus-
infected group and mAb D7 group were markedly higher
than those of the PBS group from 4 to 14 dpi (Figure 7F).
Although the TNF-α level in the mAb D7 group was
also significantly higher (P < 0.05) than the PBS group,
except at 2 and 10 dpi, the level in the mAb D7 group
was significantly lower (P < 0.01) compared with the
virus-infected and irrelevant mAb IgG groups at 6 and
14 dpi.
Discussion
H3N2 CIV is a newly identified avian influenza virus
(AIV) subtype that can infect dogs and transmit directly
from dog to dog [5,8]. CIV infection has been reported
in several countries, including South Korea and China
[9,10,37]. It is important to develop a set of measures to
prevent and control CIV infection in dogs.
Antibody-mediated passive immunity can provide pro-
tection against invading pathogens [38,39]. In this study,
we developed seven mAbs against JS/10, whose patho-
genicity has been characterized both in mice [8] and
dogs [40]. Among them, four mAbs reacted with HA.
The HA glycoprotein is the primary target of antibodies
that confer protective immunity to influenza viruses
[41]. Therefore, the generation of neutralizing antibodiesagainst antigenic sites on the HA glycoprotein is re-
garded as a criterion for evaluating immunity to in-
fluenza viruses and is believed to constitute the main
correlate of protection [42,43]. Anti-HA globular head
mAbs have potent neutralizing activity against homolo-
gous strains, but have very limited breadth of reactivity
because of the high variability of amino-acid changes in
the HA1 globular head [44]. HA2, which is the HA stalk,
however, is a conserved region of HA among all influ-
enza A virus subtypes [33,45] and is responsible for the
fusion of the virus and the endosomal membrane during
the entry of the virus into the cell [20]. Here, western
blotting showed that MAb D7 recognized the HA2
domain of H3, and had highest neutralization activities.
Although MAb D7 lacked HI activity, some previous
studies reported that a lack of in vitro HI activity of
anti-HA2 MAbs does not rule out protective activity
in vivo [33,45]. Therefore, we selected the anti-HA2
MAb D7 for further evaluation in regards to protection
against different influenza virus strains.
To investigate the protection of mAb D7 against
homologous and heterologous strains of H3N2 influenza
viruses, we selected three virus strains to perform the
challenge experiment in mice, including two strains of
CIV (JS/10 and GD/12) and one strain of swine
influenza virus (SIV) (SD/05). Considering that almost
all H3N2 CIV isolates reported were not lethal to mice
or dogs in challenge experiment [5,8,10,15,40], we
evaluated the protection efficacy by body weights, viral
loads and histological lesions. Body weight loss is the
parameter most commonly used to evaluate influenza
viral pathogenicity in mice [46]. Our study shows that all
three virus strains could remarkably reduce the growth
rate of the mice after infection, while pretreatment with
mAb D7 helped to control the declination to some
extent. From the pathological point of view, the lung,
heart and brain in mAb D7 treated groups showed
markedly fewer lesions compared with the virus-infected
group and mAb IgG group, with all virus strains. The
pathological scores of the lungs in mAb D7 group were
lower than those in the virus-infected group and mAb
IgG group, suggesting that mAb D7 could mitigate the
damage caused by influenza virus. These results suggest
that mAb D7 could offer a protective effect against the
three virus strains.
To further evaluate the effects of the anti-influenza
virus mAb, we monitored viral loads by real-time PCR.
The mAb D7 decreased the viral loads in the lungs to
significantly lower levels, relative to those in the virus-
infected group and mAb IgG group. Similar results were
also found in other tissues. For JS/10, the virus in the
brain and other organs of all three mice treated with
mAb D7 had been cleared by 10 dpi, except for the
lungs. For virus GD/12, the application of mAb D7
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days earlier than that in the other two groups; moreover,
there was no detectable virus RNA at 14 dpi. For virus
SD/05, a slower rate of clearance of viral load was ob-
served. This virus could persist and be detected in most
tissues in the mAb D7 group until 14 dpi, but virus in
the intestine and feces had been cleared by 14 dpi. These
results indicate that protection against the virus strains
provided by mAb D7 might be caused by earlier clea-
rance of the virus from the tissues or shortening the time
of virus shedding. A previous study has reported that
mAbs could reduce the period of virus clearance [23].
Our study indicates that mAb D7 could provide good
protection against challenge with homologous, as well as
heterologous, virus strains of H3N2 influenza virus. This
finding was in accordance with a previous report [47]
that HA2 mAbs are highly cross-reactive among strains
of the same subtype, and even within different subtypes.
In spite of this, we found that this mAb was relatively
less effective against the swine-lineage than canine-
lineage H3 virus strains. Sequence analysis of amino
acids showed that JS/10 had higher sequence identity to
canine-lineage GD/12 (98.6%) than to swine-lineage
SD/05 (84.8%), with 3 and 16 different amino acids,
respectively, in HA2 (data not shown). The difference in
amino acid sequence may affect antigen-antibody
recognition. This may explain why the mAb induced by
canine-lineage influenza virus strain JS/10 is not strong
enough to react against more distantly related strains
within the same subtype.
Cytokines are important in establishing an innate im-
mune response, as well as in determining the magnitude
of the inflammatory response to influenza virus infec-
tion. The most important feature of the mechanism of
immune suppression with influenza virus H5N1 is the
cytokine storm [11,48]. Here, to gain a better under-
standing of how virus infection and mAb treatment
affected host immune response, we analyzed the levels
of IFN-γ and TNF-α in the lung.
An important finding in this study is that the TNF-α
levels peaked two days later than IFN-γ levels in all
groups. A previous study showed similar results: IFN-γ
and TNF-α in the lungs of pigs infected with human
H1N1 influenza virus peaked at 3 dpi, and 6 dpi respec-
tively [49]. IFN-γ has important immune-regulatory
functions and antiviral activity, and is primarily pro-
duced by natural killer (NK) and T cells. NK cells are a
major player in innate immune responses. We specu-
lated that early production of IFN-γ during infection
probably arises from NK cells, whereas TNF-α functions
relatively late in the inflammatory cycle induced by in-
fection, at a time when virus is already being contained
and the response is centered on resolution of the inflam-
mation [50,51]. TNF-α in mice challenged by JS/10 andSD/05 maintained higher levels until 14 dpi. A previous
study demonstrated that the depletion of TNF-α in
influenza or respiratory syncytial virus-infected animals
significantly reduced pulmonary inflammation and cyto-
kine production, without compromising viral clearance
[52]. We speculated that the elevated level of TNF-α at
14 dpi might be correlated with the uncleared virus
loads in the lungs.
In the present study, three strains of H3N2 CIV were
shown to induce elevated levels of cytokines in the lungs.
This was in agreement with previous reports on H3N2
CIV [37,53]. During H5N1 influenza virus infection, the
elevated pro-inflammatory cytokine response has been
proposed as the main cause of the increased severity of
the disease [54]. The study of Lee et al. [55] reported that
the levels of IFN-γ and TNF-α in the lungs of dogs in-
fected with H3N2 influenza virus increased quickly, while
the infected dogs developed severe bronchointerstitial
pneumonia accompanied with massive infiltration of im-
mune cells. This result suggests that the dysregulation of
chemokines during H3N2 CIV infection might contribute
to viral pneumonia characterized by extensive immune
cell infiltration. In support of this hypothesis, we observed
that elevated levels of cytokines accompanied the clinical
manifestations in the CIV infected dogs.
We found that IFN-γ and TNF-α levels in the mAb D7
group were significantly lower than in the virus-infected
group or mAb IgG group, while the histopathological
findings showed more significant lesions in lungs of mice
from the latter two groups than in the mAb D7 group.
These observations indicate that mAb D7 treatment may
reduce the virus-induced cytokine production and patho-
logical lesions caused by virus infection. The effect is likely
to be mediated by inhibition of CIV replication by the
mAb. Fritz et al. [50] reported that active influenza virus
replication is required for the induction of potent pro-
inflammatory, regulatory and chemotactic factors.
Our study and a previous report [55] demonstrate that
active replication of CIV in the canine respiratory system
results in intense inflammatory responses. Considering
that it is important for the host to maintain a balance of
the cytokine levels, we speculated that inhibition of the
inflammatory cytokine response might offer a therapy
for CIV infection. However, Salomon et al. [56] demon-
strated that inhibition of the cytokine response during
H5N1 influenza virus infection is not sufficient to pro-
tect against death, and proposed that therapies targeting
the virus would be preferable.
In conclusion, our results suggest that the HA2-specific
mAb D7 could contribute to early recovery from influenza
infection with different H3N2 virus strains. This mAb will
further our understanding of the antigenic properties of
H3N2 virus and might contribute to the prevention and
control of H3N2 virus epidemic in dogs.
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Additional file 1: Viral RNA detection in collected samples of mice
inoculated with virus strain JS/10. Numbers 1, 2 and 3 represent the
three mice euthanized from each group at different dpi. + represents
viral loads in terms of mean log10 number of copies/g of RNA. Numbers
of +’s represent the magnitude of RNA copies.
Additional file 2: Viral RNA detection in collected samples of mice
inoculated with virus strain GD/12. Numbers 1, 2 and 3 represent the
three mice euthanized from each group at different dpi. + represents
viral loads in terms of mean log10 number of copies/g of RNA. Numbers
of +’s represent the magnitude of RNA copies.
Additional file 3: Viral RNA detection in collected samples of mice
inoculated with virus strain SD/05. Numbers 1, 2 and 3 represent the
three mice euthanized from each group at different dpi. + represents
viral loads in terms of mean log10 number of copies/g of RNA. Numbers
of +’s represent the magnitude of RNA copies.
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